Market Chatter: US FDA Misses Deadline for Full Approval of Novavax's Covid-19 Vaccine

MT Newswires Live04-02

A US approval of Novavax's (NVAX) COVID-19 vaccine is in limbo after the Food and Drug Administration missed a deadline for a full approval of the treatment, The Wall Street Journal reported Wednesday.

The FDA previously allowed emergency use of Novavax's vaccine and the agency's decision would have determined whether to grant the vaccine a normal, full approval, the report said, citing people familiar with the matter.

Novavax's application is still reportedly pending and could be approved by the agency at any time, the sources said.

Novavax and the FDA did not immediately respond to requests for comment from MT Newswires.

NVAX shares were up 3% in recent trading.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 6.18, Change: +0.18, Percent Change: +3.02

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2524419756?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-04-03 00:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524419756","market":"hk","top_or_hot":-1,"title":"Market Chatter: US FDA Misses Deadline for Full Approval of Novavax's Covid-19 Vaccine","media":"MT Newswires Live","content":"<html><body><p> A US approval of Novavax's (NVAX) COVID-19 vaccine is in limbo after the Food and Drug Administration missed a deadline for a full approval of the treatment, The Wall Street Journal reported Wednesday.</p><p>The FDA previously allowed emergency use of Novavax's vaccine and the agency's decision would have determined whether to grant the vaccine a normal, full approval, the report said, citing people familiar with the matter.</p><p>Novavax's application is still reportedly pending and could be approved by the agency at any time, the sources said.</p><p>Novavax and the FDA did not immediately respond to requests for comment from MT Newswires.</p><p>NVAX shares were up 3% in recent trading.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 6.18, Change: +0.18, Percent Change: +3.02</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: US FDA Misses Deadline for Full Approval of Novavax's Covid-19 Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: US FDA Misses Deadline for Full Approval of Novavax's Covid-19 Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-03 00:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> A US approval of Novavax's (NVAX) COVID-19 vaccine is in limbo after the Food and Drug Administration missed a deadline for a full approval of the treatment, The Wall Street Journal reported Wednesday.</p><p>The FDA previously allowed emergency use of Novavax's vaccine and the agency's decision would have determined whether to grant the vaccine a normal, full approval, the report said, citing people familiar with the matter.</p><p>Novavax's application is still reportedly pending and could be approved by the agency at any time, the sources said.</p><p>Novavax and the FDA did not immediately respond to requests for comment from MT Newswires.</p><p>NVAX shares were up 3% in recent trading.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 6.18, Change: +0.18, Percent Change: +3.02</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2524419756","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524419756","pubTimestamp":1743612676,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"A US approval of Novavax's  COVID-19 vaccine is in limbo after the Food and Drug Administration missed a deadline for a full approval of the treatment, The Wall Street Journal reported Wednesday.The FDA previously allowed emergency use of Novavax's vaccine and the agency's decision would have determined whether to grant the vaccine a normal, full approval, the report said, citing people familiar with the matter.Novavax's application is still reportedly pending and could be approved by the agency at any time, the sources said.Novavax and the FDA did not immediately respond to requests for comment from MT Newswires.NVAX shares were up 3% in recent trading.Price: 6.18, Change: +0.18, Percent Change: +3.02","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BK4547":"WSB热门概念","BNTX":"BioNTech SE","BK4585":"ETF&股票定投概念","BK4568":"美国抗疫概念","BK4588":"碎股"},"translate_title":"市场热议：美国FDA错过全面批准Novavax新冠疫苗的最后期限","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1,"NVAX":1},"content_text":"A US approval of Novavax's (NVAX) COVID-19 vaccine is in limbo after the Food and Drug Administration missed a deadline for a full approval of the treatment, The Wall Street Journal reported Wednesday.The FDA previously allowed emergency use of Novavax's vaccine and the agency's decision would have determined whether to grant the vaccine a normal, full approval, the report said, citing people familiar with the matter.Novavax's application is still reportedly pending and could be approved by the agency at any time, the sources said.Novavax and the FDA did not immediately respond to requests for comment from MT Newswires.NVAX shares were up 3% in recent trading.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: 6.18, Change: +0.18, Percent Change: +3.02","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2524419756"}